IMMX - Immix Biopharma, Inc.

QQQ $ 592.61 $ 0.00 (0 %)

DIA $ 455.78 $ 0.00 (0 %)

SPY $ 653.84 $ 0.00 (0 %)

TLT $ 91.53 $ 0.00 (0 %)

GLD $ 399.82 $ 0.00 (0 %)

Previous Close

$ 2.7

Open

$ 2.64

Bid

$ 2.32 x 5

Ask

$ 2.80 x 100

Day's Range

-- - --

52 Week Range

$ 1.34 - $ 3.20

Volume

687,747

Average Volume

Market Cap

77.85M

Beta (5Y Monthly)

$ 0.98

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2025	06-30-2025	10-Q
2	05-08-2025	03-31-2025	10-Q
3	03-24-2025	12-31-2024	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-12-2024	06-30-2024	10-Q
6	05-09-2024	03-31-2024	10-Q
7	03-29-2024	12-31-2023	10-K
8	11-10-2023	09-30-2023	10-Q
9	08-11-2023	06-30-2023	10-Q
10	05-12-2023	03-31-2023	10-Q
11	03-27-2023	12-31-2022	10-K
12	11-09-2022	09-30-2022	10-Q
13	08-12-2022	06-30-2022	10-Q
14	05-13-2022	03-31-2022	10-Q
15	03-28-2022	12-31-2021	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Immix Biopharma To Present An Abstract On ...
10/07/2025 20:10:39

Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leade...

$immix-biopharma-surpasses-50-enrollment-in-nexicart-2-trial-for-car-t-nxc-201-in-relapsedrefractory-al-amyloidosis-advancing-toward-bla-submission$

Immix Biopharma Surpasses 50% Enrollment I...
09/18/2025 17:32:55

– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL ...

HC Wainwright & Co. Maintains Buy on Immix...
09/12/2025 10:35:28

HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target ...

12 Health Care Stocks Moving In Monday's A...
09/08/2025 21:07:27

Immix Biopharma Gains Strategic Investment...
09/08/2025 20:08:02

Immix Biopharma, Inc. ("Immix", "Company", "We" or "Us" or "IMMX"), a clinical-stage bi...

Immix Biopharma Advances NXC-201 Cell Ther...
08/06/2025 16:32:21

– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) –– Company plans to partner-out Other Serious Disease...

$immix-biopharma-accelerates-us-nexicart-2-clinical-trial-in-relapsedrefractory-al-amyloidosis-says-it-is-on-track-for-first-bla-approved-cell-therapy-in-unaddressed-orphan-indication$

Immix Biopharma Accelerates U.S. NEXICART-...
07/07/2025 13:37:47

– National Footprint of NEXICART-2 Trial Sites Expanded –– On track for first Biologics License Application (BLA) approved cel...

HC Wainwright & Co. Reiterates Buy on Immi...
06/04/2025 11:18:47

HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $7 price target.

Immix Biopharma Files For Offering Of Up T...
06/03/2025 19:12:48

-SEC Filing

Immix Biopharma Reports NEXICART-2 Phase 1...
06/03/2025 18:57:36

Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meet...

12 Health Care Stocks Moving In Friday's I...
05/23/2025 17:06:46

Immix Biopharma Says 14 U.S. Sites Activel...
05/23/2025 13:07:38

– Patient enrollment exceeding expectations –– 14 U.S. sites actively enrolling; 10 U.S. sites added since last update –– Antic...

12 Health Care Stocks Moving In Friday's P...
05/23/2025 12:08:30

Market-Moving News for May 23rd
05/23/2025 11:07:46

OKLO: 24% | Shares of OKLO and nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boos...

Why Intuit Shares Are Trading Higher By Ov...
05/23/2025 09:09:44

12 Health Care Stocks Moving In Thursday's...
05/22/2025 21:05:56

Immix Biopharma Publishes And Presents Res...
05/22/2025 20:05:18

– NXC-201 demonstrated a complete response (CR) rate of 71% (5/7 patients) –– No relapses recorded to-date; no safety signals i...

Immix Biopharma's NXC-201 NEXICART-2 Clini...
04/23/2025 14:07:03

— Oral presentation Tuesday, June 3, 2025 in Chicago —LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (&#...

HC Wainwright & Co. Reiterates Buy on Immi...
02/10/2025 16:55:02

HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $7 price target.

Immix Biopharma Receives FDA Regenerative ...
02/10/2025 14:36:46

FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapse...